InflaRx (Group)

http://www.inflarx.de

InflaRx is a biopharmaceutical company focusing on the development of new therapeutics controlling the inflammatory response based on its proprietary technology.. InflaRx has developed a pipeline of first-in-class antibodies directed against the terminal complement component C5a. While IFX-1 focuses on the acute care space, its product candidates, IFX-2 and IFX-3, are being developed in chronic inflammatory disease indications. InflaRx was founded in 2007 and is headquartered in Jena, Germany, with long standing research collaborations in the US and China. The team consists of renowned experts in complement research and clinical acute care. InflaRx is privately owned and financed by bm-t Beteiligungsmanagement Thüringen Gmbh, KfW banking group and various international family offices. *

	Start	2007-01-01 established
	Industry	anti-inflammatory drug
	Industry 2	IFX-1 (InflaRx)
	Person	Riedemann, Niels C. (InflaRx 200803 Managing Director + founder)
	Person 2	Christ, Arnd (InflaRx 201506– CFO before Proteros + MediGene + NovImmune + Probiodrug + Hoechst)

	Region	Jena
	Country	Germany
	Street	2 Winzerlaer Str.
	City	07745 Jena
		Address record changed: 2017-11-13

Basic data	Employees	n. a.
	Currency	EUR
	Profit	-29,815,000 (2018-12-31)
	Cash	115,200,000 (2018-03-31)

		* Document for ï¿½About Sectionï¿½: Merck & Co., Inc.. (1/11/16). "Press Release: Merck Acquires IOmet Pharma and Expands Immuno-Oncology Development Program". Kenilworth, NJ.

		Record changed: 2019-06-03